252 related articles for article (PubMed ID: 2522911)
21. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
Grimm EA; Wilson DJ
Cell Immunol; 1985 Sep; 94(2):568-78. PubMed ID: 3928175
[TBL] [Abstract][Full Text] [Related]
22. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
24. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
25. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
Alessi DM; Hutcherson RW; Mickel RA
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients.
Karimine N; Nanbara S; Arinaga S; Asoh T; Ueo H; Akiyoshi T
J Surg Oncol; 1994 Mar; 55(3):179-85. PubMed ID: 8176929
[TBL] [Abstract][Full Text] [Related]
27. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
[TBL] [Abstract][Full Text] [Related]
29. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma.
Ebihara T; Koyama S; Fukao K; Osuga T
Cancer Immunol Immunother; 1989; 28(3):218-24. PubMed ID: 2522349
[TBL] [Abstract][Full Text] [Related]
32. Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2.
Chakraborty A; Chakraborty NG; Chattopadhyay U
Tumori; 1994 Jun; 80(3):233-7. PubMed ID: 8053083
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
34. An ongoing in vivo immune response affects the abundancy and differentiation of lymphokine-activated killer cell precursors, but does not influence their broad spectrum target reactivity.
Vanhaesebroeck B; Grooten J; Fiers W
J Immunol; 1989 Aug; 143(4):1396-402. PubMed ID: 2787365
[TBL] [Abstract][Full Text] [Related]
35. The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunological study.
Cortesina G; De Stefani A; Galeazzi E; Bussi M; Giordano C; Cavallo GP; Jemma C; Vai S; Forni G; Valente G
Acta Otolaryngol; 1991; 111(2):428-33. PubMed ID: 2068931
[TBL] [Abstract][Full Text] [Related]
36. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
37. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Cell Immunol; 1986 Jun; 100(1):149-57. PubMed ID: 2874890
[TBL] [Abstract][Full Text] [Related]
38. Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma.
Arinaga S; Karimine N; Nanbara S; Inoue H; Nakashima H; Ueo H; Akiyoshi T
J Surg Oncol; 1995 Jan; 58(1):44-9. PubMed ID: 7823572
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
40. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
